Chapter 007

Adrenergic Antagonists

Michael T. Piascik and Peter W. Abel

CITED REFERENCES

  1. Ahlquist RP: A study of adrenotropic receptors. Am J Physiol 153:586-600, 1948. PUBMED Abstract
  2. Alderman EL, Coltart DJ, Wettach GE, et al: Coronary artery syndromes after sudden propranolol withdrawal. Ann Intern Med 81:625-627, 1974. PUBMED Abstract
  3. Brogden RN, Heel RC, Speight TM, et al: Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14:163-197, 1977. PUBMED Abstract
  4. Cass R, Spriggs TLB: Tissue amine levels and sympathetic blockade after guanethidine and bretylium. Br J Pharmacol 17:442-450, 1961. PUBMED Abstract
  5. Chidsey CA, Braunwald E, Morrow AG, et al: Myocardial norepinephrine concentration in man: effects of reserpine and of congestive heart failure. N Engl J Med 269:653-658, 1963. PUBMED Abstract
  6. Cleaveland CR, Shand DG: Effect of route of administration on the relationship between adrenergic blockade and plasma propranolol level. Clin Pharmacol Ther 13:181-185, 1972.
  7. Clifford GM, Farmer RD: Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 38:2-19, 2000. PUBMED Abstract
  8. Coltart DJ, Gibson DG, Shand DG: Plasma propranolol levels associated with suppression of ventricular ectopic beats. BMJ 1:490-491, 1971.
  9. Dale HH: On some physiological actions of ergot. J Physiol (London) 34:163-206, 1906. PUBMED Abstract
  10. Davis LD, Temte JV: Effects of propranolol on the transmembrane potentials of ventricular muscle and Purkinje fibers of the dog. Circ Res 22:661-677, 1968. PUBMED Abstract
  11. Engelman K, Horwitz D, Jequier E, et al: Biochemical and pharmacologic effects of α-methyltyrosine in man. J Clin Invest 47:577-594, 1968. PUBMED Abstract
  12. Feuerstein G, Yue TL, Ma X, et al: Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 41:17-24, 1998. PUBMED Abstract
  13. Frantz RP: Beta blockade in patients with congestive heart failure. Postgrad Med 108:103-106, 109-110, 116-118, 2000. PUBMED Abstract
  14. Garvey HL, Ram N: Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs. J Pharmacol Exp Ther 194:220-233, 1975. PUBMED Abstract
  15. Gauthier C, Langin D, Balligand J-L: β3-Adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21:426-431, 2000. PUBMED Abstract
  16. Hersh EV, Moore PA, Papas AS, et al: Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults. J Am Dent Assoc 139:1080-1093, 2008.
  17. Hoffman BB, Lefkowitz RJ: Alpha-adrenergic receptor subtypes. N Engl J Med 302:1390-1396, 1980. PUBMED Abstract
  18. Kirby RS: Clinical pharmacology of α1-adrenoceptor antagonists. Eur Urol 36(suppl 1):48-53, 1999. PUBMED Abstract
  19. McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 62:633-653, 2002.
  20. Messerli FH, Grossman E: Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and lipid lowering treatment to prevent heart attack trial. Curr Hypertens Rep 2:241-242, 2000. PUBMED Abstract
  21. Nickerson M, Goodman LS: Pharmacological properties of a new adrenergic blocking agent: N, N-dibenzyl-chloroethylamine (Dibenamine). J Pharmacol Exp Ther 89:167-185, 1947. PUBMED Abstract
  22. Nies AS, Shand DG: Clinical pharmacology of propranolol. Circulation 52:6-15, 1975. PUBMED Abstract
  23. Packer M: Therapeutic options in the management of chronic heart failure: is there a drug of first choice? Circulation 79:198-204, 1989.
  24. Pettinger WA, Oates JA: Supersensitivity to tyramine during monoamine oxidase inhibition in man: mechanism at the level of the adrenergic neuron. Clin Pharmacol Ther 9:341-344, 1968. PUBMED Abstract
  25. Rozec B, Gauthier C: β3-Adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111:652-673, 2006. PUBMED Abstract
  26. Schwinn DA, Price RR: Molecular pharmacology of human α1-adrenergic receptors: unique features of the α1A-subtype. Eur Urol 36(suppl 1):7-10, 1999. PUBMED Abstract
  27. Starke K: Presynaptic α-autoreceptors. Rev Physiol Biochem Pharmacol 107:73-146, 1987. PUBMED Abstract
  28. Stephen SA: Unwanted effects of propranolol. Am J Cardiol 18:463-472, 1966. PUBMED Abstract
  29. Stokes GS, Oates HF: Prazosin: new alpha-adrenergic blocking agent in the treatment of hypertension. Cardiovasc Med 3:41-57, 1978.
  30. Strosberg AD: Structure and function of the β3-adrenergic receptor. Annu Rev Pharmacol Toxicol 37:421-450, 1997. PUBMED Abstract
  31. Tavares M, Goodson JM, Studen-Pavlovich D, et al: Reversal of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients. J Am Dent Assoc 139:1095-1104, 2008. PUBMED Abstract
  32. Westerlund A: Central nervous system side-effects with hydrophilic and lipophilic β-blockers. Eur J Clin Pharmacol 28(suppl):73-76, 1985. PUBMED Abstract
  33. Yagiela JA: Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. Part V of a series. J Am Dent Assoc 130:701-709, 1999. PUBMED Abstract
  34. Yoshimura N, Kaiho Y, Miyazato M, et al: Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 377:437-448, 2008.
  35. Zimmerman TJ, Kaufman HE: Timolol: a β-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 95:601-604, 1977.

GENERAL REFERENCES

  1. Bavitz JB: Dental management of patients with hypertension, Dent Clin North Am 50:547-562, 2006. PUBMED Abstract
  2. Carter LM, McHenry IDS, Godlington FL, et al: Prescribed medication taken by patients attending general dental practice: changes over 20 years, Br Dent J 203:E8, 2007.
  3. Herman WW, Konzelman JL Jr, Prisant LM: New national guidelines on hypertension: a summary for dentistry, J Am Dent Assoc 135:576-584, 2004. PUBMED Abstract
  4. Little JW, Falace DA, Miller CS, et al: Dental management of the medically compromised patient, ed 7, St. Louis, 2008, Mosby/Elsevier.
  5. Lowe FC: Role of the newer alpha,-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms, Clin Ther 26:1701-1713, 2004. PUBMED Abstract
  6. Moore PA, Gage TW, Hersh EV, et al: Adverse drug interactions in dental practice: professional and educational implications, J Am Dent Assoc 130:47-54, 1999. PUBMED Abstract
  7. Reiter MJ: Cardiovascular drug class specificity: b-blockers, Prog Cardiovasc Dis 47:11-33, 2004. PUBMED Abstract
  8. Srinivasan S, Radomski S, Chung J, et al: Intraoperative floppy-iris syndrome during cataract surgery in men using alpha-blockers for benign prostatic hypertrophy, J Cataract Refract Surg 33:1826-1827, 2007. PUBMED Abstract